|

NEO212 Oral Capsule Clinical Trials

1 actively recruiting trial across 1 location

Also known as: POH-TMZ

Pipeline

Phase 1/2: 1

Top Sponsors

  • Neonc Technologies, Inc.1

Indications

  • Mismatch Repair Deficient Colorectal Cancer1
  • Mismatch Repair Deficient Solid Malignant Tumor1
  • Diffuse Astrocytoma, IDH-Mutant1
  • Microsatellite Instability-High Colorectal Cancer1
  • Microsatellite Instability-High Solid Malignant Tumor1

Beverly Hills, California1 trial

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Precision NextGen Oncology

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.